A Worsening Problem in ALS: Insurance Barriers Between Drug Approvals and Patient Access

Authors

DOI:

https://doi.org/10.17161/rrnmf.v5i1.21232

Keywords:

Riluzole, Edaravone, Taurursodiol, Phenylbutyrate

Metrics

File downloads
390
Mar 01 '24Mar 04 '24Mar 07 '24Mar 10 '24Mar 13 '24Mar 16 '24Mar 19 '24Mar 22 '24Mar 25 '24Mar 28 '249
|

Downloads

Downloads

Published

2024-03-01

Issue

Vol. 5 No. 1 (2024)

Section

New Discoveries and Original Research

License

Copyright (c) 2024 Richard Bedlack MD PhD, Daragh Heitzman MD, Jeremy Shefner MD PhD

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

Bedlack, R., Heitzman, D., & Shefner , J. (2024). A Worsening Problem in ALS: Insurance Barriers Between Drug Approvals and Patient Access. RRNMF Neuromuscular Journal, 5(1). https://doi.org/10.17161/rrnmf.v5i1.21232